Treatment of Obstetric Hemorrhage with Fibrinogen Concentrate

Ayca Sultan Sahin
Sureyya Ozkan

Background: Postpartum hemorrhage (PPH) is related to several factors but is frequently associated with coagulopathy with maternal mortality. Fibrinogen is a very important agent for bleeding. When its concentration is decreased, severe surgical blood loss may occur. Here, we investigate the association of postpartum bleeding characteristics with evolution of PPH in patients who were taking fibrinogen concentrate (FC).

Material/Methods: PPH patients' demographic parameters, outcome variables, and laboratory findings before and at ICU were recorded between January 2015 and July 2017. The duration of ICU stay and plasmapheresis, renal replacement therapy, maternal-fetal deaths, RBC, FFP, and PC replacement were calculated.

Results: Group I: Fibrinogen levels were ≤150 mg/dl (n: 31), Group II: Fibrinogen levels were >151 mg/dl (n: 18). In the peroperative period, there was no difference between the 2 groups in terms of RBC, FFP, or PC transfusion. In intraoperative and ICU admission period, patients in Group I had higher INR, APTT, and PT values than in the other group. FC replacement according to fibrinogen level was given, ranging from 1 to 6 gr in Group I and 1–2 gr in Group II intraoperatively and at ICU 2–8 gr FC was given in both groups. In the intraoperative and ICU admission period, blood transfusion requirements of patients after fibrinogen replacement were evaluated and there was no statistically significant difference between groups. There were no differences between groups in duration of intensive care unit stay, hospital stay, and mechanical ventilation.

Conclusions: Adequate FC therapy prevents unnecessary RBC, FFP, and PC replacement and prevents complications and volume overload.

MeSH Keywords: Fibrinogen • Obstetrics • Postpartum Hemorrhage

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/914234
**Background**

Postpartum hemorrhage (PPH) is related to several factors and is frequently associated with coagulopathy of dramatic initiation. PPH is a major cause of maternal mortality and morbidity. It causes increased risk of mechanical ventilation, and hysterectomy, and prolongs intensive care unit and hospital stays [1–3]. Coagulation, especially thrombocytopenia, is affected by pregnancy. The procoagulant factors increase and fibrinolysis is reduced [4]. With circulating volume expansion, effective replacement fresh frozen plasma (FFP), red blood cells (RBC), and platelet concentrate (PC) (including coagulation factors) is very important for managing PPH [5,6]. Fibrinogen is a very important agent for bleeding, and when its concentration decreases, severe surgical blood loss may happen [7–9].

Fibrinogen is an essential endogenous component of hemostasis, and its plasma concentration increases during pregnancy [10]. Blood loss results in coagulopathy and reduced fibrinogen levels. Massive transfusion is frequently used to treat hemorrhage, but can itself result in dilutional coagulopathy. Indeed, fibrinogen is the first coagulation factor to decrease to a critically low level during major blood loss and replacement with RBC [11]. Observational studies of patients with PPH indicate that a low fibrinogen concentration in the initial stage of PPH is associated with excessive subsequent bleeding and blood transfusion [12].

At term, hemostasis is tipped towards a prothrombotic state, along with levels of all procoagulant factors, especially marked for fibrinogen, von Willebrand factor, and factor VIII, but not factor XI [12,13]. The fibrinogen level is 4–6 g/l, compared with the non-pregnant normal range of 2–4 g/l [14,15]. These changes result in shorter prothrombin and activated partial thromboplastin times (PT/aPTT), sometimes below the normal laboratory range, and a large increase in thromboelastographic parameters [16]. The platelet count may fall during pregnancy (gestational thrombocytopenia), although this is rarely to a level that significantly contributes to the risk of bleeding [17].

FC is produced from human plasma but has viral inactivation and does not require cross-match or thawing before use [21]. However, use of RBC, FFP, and PC is associated with several transfusion-related complications [22]. Recent studies recommended that with fibrinogen concentrate (FC) replacement, treatment can efficiently obtain hemostasis for PPH [18–20].

The identification of prepartum fibrinogen levels might be useful for prediction of PPH. In the present study, we present our experience in managing PPH and discuss clinically important outcomes in PPH in an obstetric hospital, which is the largest in our region, and show the efficacy of FC for treating coagulopathy in plasma fibrinogen levels.

**Material and Methods**

This study was performed in the Anesthesiology and Reanimation Clinic of a tertiary training hospital in Turkey. After delivery and post-partum assessment, patients who require intensive care for postpartum complications are admitted to the ICU. We retrospectively identified patients with PPH who delivered at our hospital or surrounding centers (mostly state hospitals) and were admitted to the ICU between January 2015 and July 2017.

Medical records were reviewed and the data recorded were demographic parameters and pregnancy outcome variables (i.e., age, parity, gestational age, mode of delivery, accompanying obstetric disorders, and gestational period), and laboratory findings before and at ICU admission (i.e., complete blood count, coagulation tests, liver enzyme levels, renal function tests, and fibrinogen). We recorded the duration of ICU stay and specific interventions performed there, including mechanical ventilation, hemofiltration, dialysis, plasmapheresis, and administration of fresh frozen plasma, unit of erythrocytes, platelets, infusion of vasoactive drugs and fibrinogen infusion, plasmapheresis, and renal replacement therapy. Other conservative treatment (e.g., antihypertensive drugs and vasoactive drugs) were administered according to the patient’s clinical conditions. Maternal mortality and fetal mortality rates were calculated.

The exclusion criteria of study were under the age of 18, known thrombophilic disease, and PPH patients that were not administered fibrinogen concentrate.

The study had ethics approval number 2018.9.19.

The clinical trial registration number of this study is NCT: 03723200 (http://clinicaltrials.gov/show/NCT03723200).

**Results**

Demographic data, ICU conditions, and outcome of patients are shown in Figure 1 and Tables 1, 2.

Six patients had HELLP syndrome and all were in Group I. Clinical parameters and fibrinogen concentrations are described in Tables 3–8. Two groups are described: Group I consisted of patients whose fibrinogen levels were ≤150 mg/dl (n: 31) and Group II consisted of patients whose fibrinogen levels were >151 mg/dl (n: 18).

In the intraoperative period, fibrinogen levels of 49 patients were measured. Fibrinogen levels were found to be ≤150 in 63.3% of patients. According to the results obtained from the comparison of blood counts according to the fibrinogen levels
of the patients, there was no statistically significant differences between Group I and Group II in white blood cell count (WBC), hematocrit (Htc), platelet count (Plt), aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), direct bilirubin, total bilirubin, or creatinine measurements (p>0.05). However, patients in Group I had higher hemoglobin (Hb), international normalized ratio (INR), activated partial thromboplastin time (APTT), and PT values than the other group and the differences between the 2 groups were statistically significant (p<0.05; p<0.01) (Table 3). Table 4 shows fibrinogen levels (mg/dl) in the intraoperative period, at admission, and at discharge from the ICU period.

In the intraoperative period, 38 patients who were given FC according to the fibrinogen levels were 1–6 g in Group I (n=31) (mean=3.13±1.20). In Group II, 7 patients who received FC had fibrinogen levels of 1–2 g (mean 1.86±38) (Table 5). Patients with fibrinogen levels above 200 mg/dl were not given FC (FC contains 1 g of fibrinogen in each vial).

We evaluated units of erythrocyte transfusion, fresh frozen plasma transfusion, and platelet transfusion requirements of the patients after FC infusion, and found no statistically significant difference between the groups in terms of blood and blood products transfusion (p>0.05).

When the laboratory values were compared between the 2 groups according to the fibrinogen levels of 49 patients at admission of the ICU, we found that INR, APTT, PT, and total and direct bilirubin values were higher and the differences between the 2 groups were statistically significant (p<0.05; p<0.01) (Table 6).

At ICU admission, the amount of FC replacement was 2–8 g in Group I (n=20) (3.35±1.46). In Group II, 2–8 g FC was administered (3.72±1.57) to 25 patients (Table 7) (FC contains 1 g of Fibrinogen in each vial).

Blood transfusion requirements of patients were evaluated after FC replacement, showing no statistically significant difference between the 2 groups in terms of RBC, FFP, and PC suring ICU stay (p>0.05) (Table 7).

There were statistically significant differences between the 2 groups in values of PT, D bil, T Bil, and creatinine (p<0.05) at discharge from the ICU (Table 8).

No adverse effects were observed during treatment.
Table 1. Demographic data of patients.

| Diagnosis             | n  | %   |
|-----------------------|----|-----|
| Previa                | 12 | 21.4|
| Uterine atony         | 22 | 39.3|
| Dekolman              | 7  | 12.5|
| HELLP syndrome        | 6  | 10.7|
| Preeclampsia/Eclampsia| 4  | 7.1 |
| Other                 | 5  | 8.9 |

| Comorbidity          | n  | %   |
|----------------------|----|-----|
| None                 | 47 | 83.9|
| Comorbidity          | 7  | 12.5|
| Bleeding             | 2  | 3.6 |

| Glasgow Coma Scale   | n  | %   |
|----------------------|----|-----|
| <15                  | 44 | 78.6|
| ≥15                  | 12 | 21.4|

| Antiplatelet therapy | n  | %   |
|----------------------|----|-----|
| Yes                  | 6  | 10.7|
| No                   | 50 | 89.3|

| Mortality            | n  | %   |
|----------------------|----|-----|
| No                   | 49 | 87.5|
| Yes                  | 7  | 12.5|

| Cardiopulmonary resuscitation | n  | %   |
|--------------------------------|----|-----|
| Yes                            | 10 | 17.9|
| No                             | 46 | 82.1|

| Fetal outcome               | n  | %   |
|------------------------------|----|-----|
| Survivor                     | 44 | 78.6|
| Perinatal mortality          | 12 | 21.4|

| Mode of delivery             | n  | %   |
|------------------------------|----|-----|
| Vaginal birth                | 8  | 14.3|
| Cesarean delivery            | 48 | 85.7|

| Antihypertensive therapy     | n  | %   |
|------------------------------|----|-----|
| Yes                          | 8  | 14.3|
| No                           | 48 | 85.7|

| Vasoactive drug infusion     | n  | %   |
|------------------------------|----|-----|
| Yes                          | 19 | 33.9|
| No                           | 37 | 66.1|

| Plasmapheresis               | n  | %   |
|------------------------------|----|-----|
| Yes                          | 3  | 5.4 |
| No                           | 53 | 94.6|

| Hemofiltration or dialysis   | n  | %   |
|------------------------------|----|-----|
| Yes                          | 6  | 10.7|
| No                           | 50 | 89.3|

| Disseminated intravascular coagulation | n  | %   |
|----------------------------------------|----|-----|
| Yes                                    | 5  | 8.9 |
| No                                     | 51 | 91.1|

| Elevated liver enzymes            | n  | %   |
|-----------------------------------|----|-----|
| Yes                               | 11 | 19.6|
| No                                | 45 | 80.4|

Table 2. Intensive care unit conditions and outcome of patients.

|                         | n   | Min–Max | Mean ±SD |
|-------------------------|-----|---------|----------|
| Age (years)             | 56  | 18–49   | 31.64±6.82|
| Duration of intensive care unit stay (days) | 56  | 1–42    | 5.98±7.39 |
| Duration of hospital stay (days)          | 56  | 1–60    | 12.88±11.94|
| Mechanical ventilation (days)             | 33  | 1–40    | 5.00±8.31 |

Values are mean ± standard deviation (SD).
This study shows the effectiveness of FC in terms of plasma fibrinogen levels as the first-line treatment for coagulopathy from PPH. RBC, FFP, and PC requirement were reduced after using FC. Adequate FC therapy prevented unnecessary RBC, FFP, and PC replacement and prevented blood product-related complications and volume overload.

Low fibrinogen is associated with excessive bleeding in postpartum hemorrhage. A study showed that prescription of 1 to 4 g of fibrinogen can significantly reduce the need for blood transfusion [23]. Decrease in need for blood transfusion in those receiving fibrinogen compounds was also confirmed [24]. Akbari et al. suggested that patients receiving fibrinogen needed an average of 600–800 cm³ less blood for resuscitation compared to FFP and control groups [25].

Table 3. Intraoperative laboratory values of groups.

|               | Group I (n=31, 63.3%) | Group II (n=18, 36.7%) | P  |
|---------------|-----------------------|------------------------|----|
| WBC count (10^3 cells/μL) | 19.95±7.30            | 18.30±8.63             | 0.367 |
| Hemoglobin (g/dl) | 7.92±2.50             | 9.51±2.59              | 0.012* |
| Hematocrit (%) | 24.00±7.50            | 27.78±7.38             | 0.063 |
| Plt (10^3 cells/μL) | 108.608±610.46        | 138.014±120.04         | 0.803 |
| APTT (s)      | 55.68±37.39           | 34.77±17.30            | 0.007*** |
| PT (s)        | 24.68±20.70           | 15.23±5.11             | 0.002** |
| INR           | 1.86±1.10             | 1.48±1.22              | 0.004** |
| AST (U/L)     | 99.23±267.11          | 190.72±472.11          | 0.836 |
| ALT (U/L)     | 50.52±115.58          | 93.78±219.22           | 0.819 |
| LDH (U/L)     | 387±227.03            | 723.3±1038.89          | 0.622 |
| Serum bilirubin (mg/dl) (direct) | 1.02±2.41             | 0.98±1.86              | 0.559 |
| Serum bilirubin (mg/dl) (total) | 1.38±2.68             | 1.39±2.32              | 0.871 |
| Serum Creatinine (mg/dl) | 0.93±0.47              | 0.71±0.301             | 0.166 |

* p<0.5; ** p<.01. Values are mean ± standard deviation (SD). PT-INR – prothrombin time-international normalized ratio; APTT – activated partial thromboplastin time; WBC – white blood cell; Plt – platelet count; AST – serum aspartate aminotransferase; ALT – serum alanine aminotransferase; LDH – serum lactate dehydrogenase.

Table 4. Value of fibrinogen levels (mg/dl) in intraoperative, admission, and ICU discharge.

|               | n  | Intraoperative | n  | Admission of ICU | n  | Discharge of ICU |
|---------------|----|----------------|----|------------------|----|------------------|
| Group I       | 31 | 81.5±33.7      | 31 | 167.3±83.6       | 30 | 318.0±142.7      |
| Group II      | 18 | 291.4±104.6    | 18 | 188.2±73.1       | 18 | 325.9±146.3      |

Values are mean ± standard deviation.

Table 5. Units of blood and blood products transfused and amount of FC intraoperatively.

|               | RBC (n=36) | FFP (n=37) | PC (n=10) | FC |
|---------------|------------|------------|-----------|----|
| n Sym         | Mean ±SD   | n Sym      | Mean ±SD  | n Sym   | Mean ±SD |
| Group I       | 24         | 5.08±3.67  | 25        | 4.00±2.50 | 8        | 6.50±3.55 | 31        | 3.13±1.20 |
| Group II      | 12         | 4.08±2.84  | 12        | 3.17±2.22 | 2        | 7.00±4.24 | 7         | 1.86±0.38 |
| p             | 0.398      | 0.061      | 1.000     | –         |

Discussion

This study shows the effectiveness of FC in terms of plasma fibrinogen levels as the first-line treatment for coagulopathy from PPH. RBC, FFP, and PC requirement were reduced after using FC. Adequate FC therapy prevented unnecessary RBC, FFP, and PC replacement and prevented blood product-related complications and volume overload.
The present study showed that, in Group I, hemoglobin, INR, APTT, and PT values were lower at ICU admission and there was no significant difference between the 2 groups in terms of blood transfusion because of adequate FC replacement. Thus, complications such as excessive volume and allergic reactions due to transfusion were prevented. In addition, concentrated red blood cells lead to increased rates of infection [26]. In the peroperative period, there were no statistically significant differences between groups in terms of blood and blood product transfusion, and this was associated with good management of PPH with low fibrinogen levels.

In the intraoperative and ICU admission periods, patients in Group I (≤150 mg/dl fibrinogen) had higher INR, APTT, and PT values than the other group. Because of the fibrinogen levels of patients in Group I, bleeding parameters were expected to be higher. INR, APTT, and PT levels increased bleeding but there were no differences between amount of RBC, FFP, PC transfusion because of adequate FC replacement. Lower fibrinogen level is a direct independent risk factor before delivery, and targeted fibrinogen therapy might be warranted during severe PPH [9]. Guasch et al. showed FC was the only product that can increase mean plasma fibrinogen levels from 3.3 g/L to 4.4 g/L. In our study, FC replacement according to the fibrinogen level was given and ranged from 1 to 6 g in Group I and 1–2 g in Group II intraoperatively, and at ICU admission 2–8 g FC was given to both groups. Patients with fibrinogen levels above 200 mg/dl were not given FC.

### Table 6. Laboratory values at ICU admission.

|          | Group I (n=20, %40.8) | Group II (n=29, %59.2) | P   |
|----------|-----------------------|------------------------|-----|
| WBC count (10³ cells/µL) | 19.02±9.84           | 18.41±6.84             | 0.799 |
| Hemoglobin (g/dL)         | 8.03± 2.02            | 7.91±2.02              | 0.976 |
| Hematocrit (%)            | 23.81±6.23            | 24.00±5.93             | 0.815 |
| Plt (10³ cells/µL)        | 88.44±46.439          | 103.50±83.597          | 0.887 |
| APTT (s)                  | 52.34±34.78           | 40.08±27.52            | 0.023* |
| PT (s)                    | 21.52±8.21            | 15.18±3.26             | 0.001**|
| INR                      | 1.84±.76              | 1.21±.34               | <0.001***|
| AST (U/L)                 | 175.82±332.82         | 160.59±672.50          | 0.404 |
| ALT (U/L)                 | 239.00±580.75         | 77.5±318.62            | 0.127 |
| LDH (U/L)                 | 641.16±876.05         | 551.50±803.94          | 0.468 |
| Serum bilirubin (mg/dL) (direct) | 2.73±3.96           | 0.64±1.22              | 0.004**|
| Serum bilirubin (mg/dL) (total) | 3.74±5.40           | 1.14±2.02              | 0.010* |
| Serum Creatinine (mg/dL)  | 1.09±.63              | 0.84±.39               | 0.230 |

* p<0.5; ** p<.01. Values are mean ±SD. PT-INR – prothrombin time-international normalized ratio; APTT – activated partial thromboplastin time; WBC – white blood cell; Plt – platelet count; AST – serum aspartate aminotransferase; ALT – serum alanine aminotransferase; LDH – serum lactate dehydrogenase.

### Table 7. Units of blood and blood products transfused and amount of FC in ICU.

|          | RBC (n=36) | FFP (n=37) | PC (n=10) | FC |
|----------|------------|------------|-----------|----|
| n        | Mean ±SD   | n          | Mean ±SD  | n  | Mean ±SD |
| Group I  | 17         | 6.82±5.11  | 17        | 8.71±12.70 | 11 | 13.18±21.65 | 20 | 3.35±1.46 |
| Group II | 26         | 5.35±4.99  | 22        | 14.55±42.42 | 13 | 10.08±12.94 | 25 | 3.72±1.57 |
| p        | 0.354      | 0.528      | 0.733     | –  |

Values are mean ± standard deviation (SD) or number. FC – fibrinogen concentrate (g); FFP – fresh frozen plasma (1 Unit: 200 ml); RBC – red blood cells (1 Unit: 250 ml); PC – platelet concentrate (1 Unit: 200 ml).
Early administration of FC can be useful in the absence of viscoelastic measurements such as thrombelastography. During the intraoperative and ICU admission periods, blood transfusion requirements of patients after fibrinogen replacement were evaluated, and there was no statistically significant difference between the groups in RBC, FFP, or PC. Thus, we avoided complications such as excessive volume overload and allergic reaction.

In our study, ALT, LDH, and bilirubin levels at ICU admission were higher than at ICU discharge because of patients with HELLP syndrome (10.7%), and that includes elevated liver enzymes. HELLP syndrome is a life-threatening obstetric complication and is considered a multisystemic disorder, and also treated in the ICU. Maternal and perinatal complications are frequently observed in patients with this syndrome. Mortality among women with HELLP syndrome was linked with low platelet count, low fibrinogen level, high INR value, and high serum levels of AST, ALT, and LDH, and complications in this patient group are associated with maternal death [27]. A study reported that 30% of patients with HELLP syndrome required mechanical ventilation in the ICU [28]. In the present study, there were no differences between duration of intensive care unit stay, hospital stay, and mechanical ventilation. Longer duration of ICU stay might reflect the severity of the patient’s clinical situation.

Conclusions

Massive transfusion takes time and raises volume overload for PPH, which can cause acute lung injury and pulmonary edema. This study demonstrated that FC therapy as the first-line agent can reduce the risk of massive transfusion complications. Nevertheless, further study is needed to assess the role of FC in PPH.

Conflict of interest

None.

References:

1. Weissmann-Brenner A, Simchen MJ, Eran Zilberberg E et al: Maternal and neonatal outcomes of macrosomic pregnancies. Med Sci Monit, 2012; 18(9): 77–81
2. Seto S, Itakura A, Okagaki R et al: An algorithm for the management of coagulopathy from postpartum hemorrhage, using fibrinogen concentrate as first-line therapy. Int J Obstet Anesth, 2017; 32: 11–16
3. Gayat E, Resche-Rigon M, Morel O et al: Predictive factors of advanced interventional procedures in a multicentre severe post-partum haemorrhage study. Intensive Care Med, 2011; 37(11): 1816–25
4. Wikkelsø AJ, Edwards HM, Afshari A et al: Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: Randomized controlled trial. Br J Anaesth, 2015; 114(4): 623–33
5. Ahonen J, Stefanovic V, Lassila R: Management of post-partum hemorrhage. Acta Anaesthesiol Scand, 2010; 54: 1164–78
6. Fuller AJ, Bucklin BA: Blood product replacement for postpartum hemorrhage. Curr Obstet Gynecol, 2010; 53: 196–208

Table 8. Laboratory values at discharge from ICU.

|               | Group I (n=3, 6.3%) | Group II (n=46, 93.8%) | p    |
|---------------|---------------------|------------------------|------|
| WBC           | 37.63±6.55          | 11.57±4.01             | 0.613|
| Hb            | 7.77±1.65           | 8.51±1.50              | 0.776|
| Htc           | 24.30±6.01          | 25.47±4.29             | 0.480|
| Plt           | 47.39±40.905        | 160.86±112.66          | 0.454|
| APTT          | 84.63±9.41          | 36.52±30.92            | 0.975|
| PT            | 26.77±3.46          | 13.72±2.81             | 0.036*|
| INR           | 2.38±0.35           | 1.09±0.20              | 0.072|
| AST           | 910.67±1474.15      | 31.58±40.66            | 0.958|
| ALT           | 1027.67±1328.86     | 26.13±59.98            | 0.453|
| LDH           | 1867.33±1960.05     | 328.09±144.39          | 0.341|
| BilD          | 4.90±5.34           | 1.04±2.55              | 0.010*|
| BilT          | 5.63±6.01           | 1.41±3.08              | 0.025*|
| Creatinine    | 2.12±0.64           | 1.57±4.54              | 0.017*|

* p<0.5; ** p<.01. Values are mean ±SD. PT-INR – prothrombin time-international normalized ratio; APTT – activated partial thromboplastin time.
7. Hiippala ST, Myllyla GJ, Vahtera EM: Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg, 1995; 81: 360–65
8. Charbit B, Mandelbrot L, Samain E et al: The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost, 2007; 5: 266–73
9. Guasch E, Gilansz F: Treatment of postpartum hemorrhage with blood products in a tertiary hospital: Outcomes and predictive factors associated with severe hemorrhage. Clin Appl Thromb Hemost, 2016; 22(7): 685–92
10. Abbassi-Ghanavati M, Greer LG, Cunningham FG: Pregnancy and laboratory studies: A reference table for clinicians. Obstet Gynecol, 2009; 114: 1326–31
11. Cristina Solomon C, Gröner A, Ye J et al: Safety of fibrinogen concentrate: Analysis of more than 27 years of pharmacovigilance data. Thromb Haemost, 2015; 113: 759–71
12. Allard S, Green L, Hunt BJ: How we manage the haematological aspects of major obstetric haemorrhage. Br J Haematol 2014; 164: 177–88
13. O’Riordan MN, Higgins JR: Haemostasis in normal and abnormal pregnancy. Best Pract Res Clin Obstet Gynaecol, 2003; 17: 385–96
14. Liu X, Jiang Y, Shi H et al: Prospective, sequential, longitudinal study of coagulation changes during pregnancy in Chinese women. Int J Gynaecol Obstet, 2009; 105: 240–43
15. Szecsi PB, Jorgensen M, Klaejnbard A et al: Haemostatic reference intervals in pregnancy. Thromb Haemost, 2010; 103: 718–27
16. Hill JS, Devenie G, Powell M: Point-of-care testing of coagulation and fibrinolytic status during postpartum haemorrhage: Developing a thrombelastography-guided transfusion algorithm. Anaesth Intensive Care, 2012; 40: 1007–15
17. Collins RE, Collins PW: Haemostatic management of obstetric haemorrhage. Anaesthesia, 2015; 70(1): 78–86
18. Bell SF, Raymond R, Collins PW et al: The use of fibrinogen concentrate to correct hypofibrinogenemia rapidly during obstetric hemorrhage. Int J Obstet Anesth, 2010; 19: 218–23
19. Weinkove R, Rangarajan S: Fibrinogen concentrate for acquired hypofibrinogenemic states. Transfus Med, 2008; 18: 151–57
20. Kikuchi M, Itakura A, Miki A et al: Fibrinogen concentrate substitution therapy for obstetric hemorrhage complicated by coagulopathy. J Obstet Gynaecol Res, 2013; 39: 770–76
21. Kreuz W, Meili E, Peter-Salonen K et al: Pharmacokinetic properties of a pasteurised fibrinogen concentrate. Transfus Apher Sci, 2005; 32: 239–46
22. Stinger HK, Spinella PC, Perkins JG et al: The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma, 2008; 64: 79–85
23. Schlimp CI, Ponschab M, Voelckel W et al: Fibrinogen levels in trauma patients during the first seven days after fibrinogen concentrate therapy: A retrospective study. Scand J Trauma Resusc Emerg Med, 2016; 24(1): 29
24. Curry N, Rourke C, Davenport R et al: Fibrinogen replacement in trauma haemorrhage. Scand J Trauma Resusc Emerg Med, 2014; 22(1): 5
25. Akbari E, Safari S, Hatamabadi H: The effect of fibrinogen concentrate and fresh frozen plasma on the outcome of patients with acute traumatic coagulopathy: A quasi-experimental study. Am J Emerg Med, 2018; 36(11): 1947–50
26. Bochicchio GV, Napolitano L, Joshi M et al: Outcome analysis of blood product transfusion in trauma patients: A prospective, risk-adjusted study. World J Surg, 2008; 32(10): 2185–89
27. Gedik E, Yücel N, Sahin T et al: Hemolysis, elevated liver enzymes, and low platelet count syndrome? J Turk Gynecol Assoc, 2012; 13(1): 1–7
28. Bezircioglu I, Baloglu A, Cetinkaya B et al: Do clinical and laboratory parameters effect maternal and fetal outcomes in pregnancies complicated with hemolysis, elevated liver enzymes, and low platelet count syndrome? J Turk Gynecol Assoc, 2012; 13(1): 1–7